Literature DB >> 9029031

Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

C Uderzo1, M G Valsecchi, A Balduzzi, G Dini, R Miniero, F Locatelli, R Rondelli, A Pession, W Arcese, A Bacigalupo, P Polchi, M Andolina, C Messina, V Conter, M Aricó, S Galimberti, G Masera.   

Abstract

We compared the outcome of children with high-risk acute lymphoblastic leukaemia (HR-ALL) in first complete remission (first CR) treated with chemotherapy (CHEMO) or with allogeneic bone marrow transplantation (BMT) in a multicentre study. All children treated by the Italian Paediatric Haematology Oncology Association for HR-ALL in first CR between 1986 and 1994 were eligible for the study. 30 children were given BMT at a median of 4 months from first CR, with preparative regimens including total-body irradiation (n = 25/30). 130 matched controls for BMT patients were identified among 397 HR-ALL CHEMO patients. Matching on main prognostic factors and duration of first CR was adopted to control the selection and time-to-transplant biases. The comparative analysis was based on the results of a stratified Cox model. The estimated hazard ratios of BMT versus CHEMO at 6 months, 1 year and 2 years after CR were 1.38 (CI 0.59-3.24), 0.69 (CI 0.27-1.77) and 0.35 (CI 0.06-1.91), with an overall non-significant difference between the two groups (P = 0.34). With a median follow-up of 4 years, the disease-free survival was 58.5% (SE 9.3) in the BMT group and 47.7% (SE 4.8) in the CHEMO group, at 4 years from CR. Non-leukaemic death occurred in 4% of CHEMO and 10% of BMT patients. In the BMT group the estimated cumulative incidence of relapse at 1.5 years from CR was 31.5% (SE 8.8) and did not change thereafter, whereas in the CHEMO group the corresponding figure was 29.2% (SE 4.1) and the incidence continued to increase thereafter (48.2% (SE 4.8) at 4 years from CR). The results of this study suggest that, with respect to the CHEMO group, the higher risk of early failure in the BMT group is outweighed by the lower risk of relapse after 1 year. Results prompt the need for a prospective study, in order to demonstrate the likely advantage of BMT in HR childhood ALL in first CR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029031     DOI: 10.1046/j.1365-2141.1997.d01-2033.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Hematopoietic stem cell transplantation for leukemia.

Authors:  Alan S Wayne; Kristin Baird; R Maarten Egeler
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

2.  Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.

Authors:  Franca Fagioli; Paola Quarello; Marco Zecca; Edoardo Lanino; Carla Rognoni; Adriana Balduzzi; Chiara Messina; Claudio Favre; Roberto Foà; Mimmo Ripaldi; Sergio Rutella; Giuseppe Basso; Arcangelo Prete; Franco Locatelli
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

3.  Multivariate permutation test to compare survival curves for matched data.

Authors:  Stefania Galimberti; Maria Grazia Valsecchi
Journal:  BMC Med Res Methodol       Date:  2013-02-11       Impact factor: 4.615

4.  Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review.

Authors:  Marion K Mateos; Tracey A O'Brien; Cecilia Oswald; Melissa Gabriel; David S Ziegler; Richard J Cohn; Susan J Russell; Draga Barbaric; Glenn M Marshall; Toby N Trahair
Journal:  Pediatr Blood Cancer       Date:  2013-06-03       Impact factor: 3.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.